国际肿瘤学杂志 ›› 2013, Vol. 40 ›› Issue (1): 50-53.

• 综述 • 上一篇    下一篇

血管内皮抑制素在非小细胞肺癌中的应用

张磊, 徐建宇, 徐向英   

  1. 150081哈尔滨,哈尔滨医科大学附属第三医院放疗科(张磊、徐建宇、徐向英);黑龙江省肿瘤防治研究所(徐向英)
  • 出版日期:2013-01-08 发布日期:2013-01-15
  • 通讯作者: 徐向英,E-mail:xuxxyy@sohu.com E-mail:xuxxyy@sohu.com
  • 基金资助:

    中华国际医学交流基金会先声抗肿瘤治疗专项科研基金(CIMF-F-H001-155)

Endostatin in the treatment of non-small-cell lung cancer

ZHANG  Lei, XU  Jian-Yu, XU  Xiang-Ying   

  1. Department of Radiation Oncology, the Third Affiliated Hospital of Harbin Medical University, Harbin 150081, China

  • Online:2013-01-08 Published:2013-01-15
  • Contact: XU Xiang-Ying,E-mail:xuxxyy@sohu.com E-mail:xuxxyy@sohu.com

摘要: 血管内皮抑制素是一种新型抗肿瘤血管生成药物,通过多条途径抑制血管内皮生长因子等促血管生长因子的表达,达到抑制肿瘤血管生成的目的。该药物在非小细胞肺癌(NSCLC)治疗的基础研究及临床应用中均显示,单独使用具有一定抗肿瘤作用;联合放化疗可获得较好的近期疗效,不增加治疗相关不良反应;药物不良反应轻微,耐受性良好。

关键词: 内皮抑素类, 癌, 非小细胞肺, 放射疗法, 药物疗法

Abstract: Endostatin is a novel anti-angiogenic drug which through multiple pathway inhibits vascular endothelial growth factor expression, to achieve the purpose of the inhibition of tumor angiogenesis. The drug in the treatment of non-small-cell lung cancer in pre-clinical study and clinical application show that: used alone have anti-tumor effect; combined with radiotherapy and chemotherapy can obtain short-term curative effect, and does not increase treatment related toxicity. The adverse effect of the drug is mild and can be well tolerated.

Key words: Endostratins, Carcinoma, non-small-cell lung, Radiotherapy, Drug therapy